Ling C Chen

US Patent:

7655762, Feb 2, 2010

Filed:

Jan 6, 2006

Appl. No.:

11/327844

Inventors:

Gregory M. Landes - The Woodlands TX, US
Kyu Chung - Granger IN, US
Ling Chen - Blue Bell PA, US
Urvi Desai - The Woodlands TX, US
David Reed Powell - Houston TX, US
Seokjoo Hong - The Woodlands TX, US

Assignee:

Lexicon Pharmaceuticals, Inc. - The Woodlands TX

International Classification:

C07K 16/18

US Classification:

5303881, 5303879

Abstract:

Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

US Patent:

8092796, Jan 10, 2012

Filed:

Dec 4, 2009

Appl. No.:

12/631598

Inventors:

Gregory M. Landes - The Woodlands TX, US
Kyu Chung - Granger IN, US
Ling Chen - Blue Bell PA, US
Urvi Desai - The Woodlands TX, US
David Reed Powell - Houston TX, US
Seokjoo Hong - The Woodlands TX, US

Assignee:

Lexicon Pharmaceuticals, Inc. - The Woodlands TX

International Classification:

C07K 16/18
A61K 39/395

US Classification:

4241301, 5303879, 5303881, 4241391, 4241411, 4241421, 4241331

Abstract:

Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

US Patent:

8591891, Nov 26, 2013

Filed:

Dec 8, 2011

Appl. No.:

13/315027

Inventors:

Gregory M. Landes - The Woodlands TX, US
Kyu Chung - Granger IN, US
Ling Chen - Blue Bell PA, US
Urvi Desai - The Woodlands TX, US
David Reed Powell - Houston TX, US
Seokjoo Hong - The Woodlands TX, US

Assignee:

Lexicon Pharmaceuticals, Inc. - The Woodlands TX

International Classification:

A61K 39/395
C07K 16/18

US Classification:

4241301, 4241391, 4241411, 4241421, 4241331, 5303879, 5303881

Abstract:

Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

US Patent:

20050058649, Mar 17, 2005

Filed:

Dec 2, 2003

Appl. No.:

10/726332

Inventors:

Gregory Landes - The Woodlands TX, US
Mary Haak-Frendscho - Newark CA, US
Ling Chen - The Woodlands TX, US
Meina Liang - Danville CA, US
Xiao Feng - Union City CA, US
Xiao-Chi Jia - Los Angeles CA, US
Mark Nocerini - San Francisco CA, US

International Classification:

A61K039/395
C07K016/40

US Classification:

424146100, 530388260

Abstract:

The invention described herein relates to antibodies directed to the antigen phospholipase A2 (PLA2) and uses of such antibodies. In particular, in accordance with some embodiments of the invention, there are provided fully human monoclonal antibodies directed to the antigen PLA2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.